Incorporating the learnings from these failures into the design of new BACE-1 inhibitors therefore offers the chance to develop a 3rd generation of compounds with an improved safety profile, allowing long term treatment of AD patients. This evidence concerns the gene BACE1 and Alzheimer disease.